甲基C-Phycoerythrin 预防慢性病引起的全身性动脉高血压,避免氧化应激和血管功能障碍在剩余的功能性脏
Oscar Iván Florencio-Santiago1, Vanesa Blas-Valdivia2, José Iván Serrano-Contreras3
1Laboratorio de Metabolismo I, Departamento de Fisiología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Ciudad de México 07738, Mexico.
Marine drugs
|August 28, 2024
概括
通过减少氧化应激和血管功能障碍,C-phycoerythrin (CPE) 防止慢性病 (CKD) 进展为全身性动脉高血压 (SAH). 这种生物活性化合物为病并发症提供了潜在的治疗益处.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 慢性病 (CKD) 是一个严重的健康负担,特别是在低收入和中等收入国家.
- 系统性动脉高血压 (SAH) 是CKD的一个主要并发症,通常是晚诊断的.
- C-phycoerythrin (CPE) 是一种来自*Phormidium persicinum*的化合物,具有抗炎,抗氧化和体内脏保护作用.
研究的目的:
- 在慢性病 (CKD) 的老鼠模型中研究C-phycoerythrin (CPE) 的抗高血压作用.
- 评估CPE对CKD血液动力学参数,功能,氧化应激和血管功能障碍标志物的影响.
主要方法:
- 在Wistar大鼠中使用了5/6切除模型,分为假,假+CPE,切除 (NFx) 和NFx+CPE组.
- 在手术后的五周内,每周进行一次血液动力学评估.
- 评估了功能,氧化应激标志物,以及氨酸-血管素系统 (RAS) 和相关信号通路 (AT1R,AT2R,Mas1/p-Akt/p-eNOS) 的表达.
主要成果:
- 到第三周,CKD诱导过和全身动脉高血压 (SAH).
- 经过切除的老鼠显示AT1R上调和AT2R下调,以及Mas1/p-Akt/p-eNOS轴的变化.
- 治疗CPE减轻了损伤,保持了功能,并预防了SAH的发展.
- CPE调节了血管扩张的AT1R,AT2R和Mas1/p-Akt/p-eNOS轴,减少了氧化应激和血管功能障碍.
结论:
- 在慢性病 (CKD) 的临床前模型中,C-phycoerythrin (CPE) 在慢性病 (CKD) 的临床前模型中显示出显著的抗高血压作用.
- 通过减轻氧化应激和血管功能障碍,CPE可以防止CKD向全身性动脉高血压 (SAH) 的进展.
- 这些发现表明CPE的潜力作为一种治疗药物来管理CKD并发症.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
404
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
404
01:22Heart Failure Drugs: Diuretics
352
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
352
01:25Antihypertensive Drugs: Direct Renin Inhibitors
511
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
511
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
510
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
510
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
147
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
147